ZOMETA® Renal Cell Carcinoma Case Study Confirm The Benefits Of Dosing ZOMETA® Every 3-4 Weeks
ZOMETA - Zoledronic AcidZOMETA - Zoledronic Acid Novartis Oncology
HomeZOMETA - International SiteZOMETA - US ResidentsZOMETA - Country Sites
ZOMETA - English ZOMETA - Deutsch ZOMETA - Espanol ZOMETA - Francais ZOMETA - Italiano
ZOMETA-Videos
Blue Arrow View videos on bone
metastases and the ZOMETA
mechanism of action

Learn more about the ZOMETA(zoledronic acid) mechanism of action

 
ZOMETA European Summary of Product Characteristics
Blue Arrow For non-U.S. Healthcare Professionals: Get information about ZOMETA and its product characteristics

Learn more about ZOMETA product characteristics
 
ZOMETA Patient Case Study: Renal Cell Carcinoma ZOMETA is the current standard of care for the prevention of skeletal-related events (SREs)

Carlo V.
  • Aged 67 years
  • Retired accountant
  • Takes sculpting classes twice a week
Medical Profile The Clinical Question Reasons for ZOMETA® How to use ZOMETA® References
Page  1 2 3

Real-world results confirm the benefits of dosing ZOMETA® every 3 to 4 weeks in patients like Carlo14

  • Using alternative dosing schedules significantly compromises the benefits of ZOMETA14


Rate of SREs by dosing regimen*
Rate of SREs by dosing regimen graph
*There are limitations to the study because the results are from a retrospective claims
database analysis.



  • Treatment with ZOMETA 4 mg every 3 to 4 weeks significantly reduced the rate of skeletal morbidity (measured as number of events per month) vs no treatment14
  • No other dosing schedule is proven to protect patients from SREs2,11-13


Achieve maximum potential benefit—treat with ZOMETA 4 mg every 3 to 4 weeks



Page  1 2 3